<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[drug company Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/drug+company.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to drug company]]></description>
	<s:counts start="0" returned="20" found="78" />
	<language>en-us</language>
	<item>
		<title><![CDATA[GSK's $1B Paxil Problem Highlights Murky Disclosures From Euro Drug Companies]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005807/gsks-1b-paxil-problem-highlights-murky-disclosures-from-euro-drug-companies/]]></link>
		<description><![CDATA[GlaxoSmithKline GSK has paid $1 billion to settle lawsuits related to Paxil. The fact that it was disclosed by Bloomberg and not the company itself illustrates how lousy financial disclosure rules are in Europe and why drug companies based there cannot be trusted to tell the truth about what is...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 15 Dec 2009 03:10:31 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/financial.html"><![CDATA[Financial]]></category>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/litigation.html"><![CDATA[Litigation]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Generic drug groups raided]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fwww.ft.com%2Fcms%2Fs%2F0%2F5c4e811e-e52c-11de-9a25-00144feab49a.html&siteid=23&tag=financialtimes]]></link>
		<description><![CDATA[ European competition regulators yesterday launched a fresh set of raids on the premises of some drug companies because of concern about anti-competitive practices.This is the third set of "surprise investigations" at individual companies, following a wide-ranging inquiry into the pharmaceutical sector, ordered by the European Union competition commissioner Neelie...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 09 Dec 2009 18:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/raid.html"><![CDATA[Raid]]></category>
		<category domain="http://resources.bnet.com/topic/company+news.html"><![CDATA[Company News]]></category>
		<category domain="http://resources.bnet.com/topic/monopolies+%2526+antitrust.html"><![CDATA[Monopolies & Antitrust]]></category>
		<category domain="http://resources.bnet.com/topic/regulation+of+business.html"><![CDATA[Regulation of Business]]></category>
		<category domain="http://resources.bnet.com/topic/financial+times.html"><![CDATA[Financial Times]]></category>
	</item>
	<item>
		<title><![CDATA[FTSE Seen Opening 35-46 Points Lower]]></title>
		<link><![CDATA[http://www.bnet.com/2407-13071_23-368463.html]]></link>
		<description><![CDATA[LONDON (<a href="http://resources.bnet.com/index.php?source=ReutersUK">Reuters UK</a>) - FTSE 100  is seen opening 35-46 points lower on Friday according to financial bookmakers, extending losses from the previous session following weakness in Asia as worries about the global economy mounted after Dubai's debt problems emerged.The index is seen opening down as much as 0.9...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Thu, 26 Nov 2009 23:15:18 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/dubai.html"><![CDATA[Dubai]]></category>
		<category domain="http://resources.bnet.com/topic/ftse+100.html"><![CDATA[FTSE 100]]></category>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/ftse.html"><![CDATA[FTSE]]></category>
		<category domain="http://resources.bnet.com/topic/financial+accounting.html"><![CDATA[Financial Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/astrazeneca+plc..html"><![CDATA[AstraZeneca Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/royal+dutch+shell+plc..html"><![CDATA[Royal Dutch Shell Plc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">RDSA</category>
		<category domain="tickers">AZN,RDSA</category>
	</item>
	<item>
		<title><![CDATA[FDA Seeks Advice From Blogger; Google Solves Pharma's Ad Problems]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005281/fda-seeks-advice-from-blogger-google-solves-pharmas-ad-problems/]]></link>
		<description><![CDATA[The FDA sought the advice of John Mack, a blogger with 20,000 monthly readers who runs the Pharma Marketing Blog, on how drug companies should use the web to advertise their products. The agency usually likes to hear from lawyers, drug company executives and academics when it seeks regulatory advice....]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 12 Nov 2009 15:08:51 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/google+inc..html"><![CDATA[Google Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/advertisement.html"><![CDATA[Advertisement]]></category>
		<category domain="http://resources.bnet.com/topic/advice.html"><![CDATA[Advice]]></category>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/blogger.html"><![CDATA[Blogger]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GOOG</category>
		<category domain="tickers">GOOG</category>
	</item>
	<item>
		<title><![CDATA[In Q2, Drug Companies Lobbied to Expand Many Government Healthcare Programs]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10004023/in-q2-drug-companies-lobbied-to-expand-many-government-healthcare-programs/]]></link>
		<description><![CDATA[A look at what drug companies spent on lobbying in the second quarter of 2009 shows an interesting dichotomoy: It's a parade of selfishness that, if successful, may end up doing more to expand government-run healthcare in the U.S. than President Obama's reforms. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 01 Sep 2009 08:30:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/health+care.html"><![CDATA[Health Care]]></category>
		<category domain="http://resources.bnet.com/topic/vertical+industries.html"><![CDATA[Vertical Industries]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Ranking of 20 Drug Companies Shows Sales Force Effectiveness Reaching Plateau]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003533/ranking-of-20-drug-companies-shows-sales-force-effectiveness-reaching-plateau/]]></link>
		<description><![CDATA[A ranking of 20 drug companies by sales and marketing productivity shows that 10 companies saw upward trends in effectiveness in Q2 2009. Last quarter, 13 companies had upward trends. The numbers indicate that companies have started to reach a plateau in their efforts to wring more revenues out of...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 07 Aug 2009 14:43:11 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/sales+force.html"><![CDATA[Sales Force]]></category>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/marketing+research.html"><![CDATA[Marketing Research]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Schuler Takes Seat at Elan; Icahn Lurks in the Wings; Bad News on Tysabri]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10002685/schuler-takes-a-seat-at-elan-icahn-lurks-in-the-wings-bad-news-on-tysabri/]]></link>
		<description><![CDATA[Things are moving quickly at Elan, the illogically managed Irish drug company whose top executives work in at least three different offices that are 5,000 miles apart. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 12 Jun 2009 19:50:32 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/top+executive.html"><![CDATA[Top Executive]]></category>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/schuler.html"><![CDATA[Schuler]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Why Drug Companies Prefer Twitter Over Blogs]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10002232/why-drug-companies-prefer-twitter-over-blogs/]]></link>
		<description><![CDATA[GlaxoSmithKline has started a blog, becoming only the fourth* major drug company to launch an official unofficial voice on the web. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 19 May 2009 19:28:14 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/blog.html"><![CDATA[Blog]]></category>
		<category domain="http://resources.bnet.com/topic/twitter.html"><![CDATA[Twitter]]></category>
		<category domain="http://resources.bnet.com/topic/blogging.html"><![CDATA[Blogging]]></category>
		<category domain="http://resources.bnet.com/topic/internet.html"><![CDATA[Internet]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[IOM Report Won't Have Much Impact on Big Pharma]]></title>
		<link><![CDATA[http://industry.bnet.com/healthcare/1000654/iom-report-wont-have-much-impact-on-big-pharma/]]></link>
		<description><![CDATA[The recent Institute of Medicine IOM report on the relationship between physicians and the drug industry shows how far weâ€™ve come in the last few years, and how far we still have to go. In 2006, ten leading academicians and the head of the Association of American Medical Colleges AAMC...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 14 May 2009 16:08:34 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/accme.html"><![CDATA[ACCME]]></category>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/education.html"><![CDATA[Education]]></category>
		<category domain="http://resources.bnet.com/topic/ken+terry.html"><![CDATA[Ken Terry]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/physician.html"><![CDATA[Physician]]></category>
	</item>
	<item>
		<title><![CDATA[Ranking of 20 Drug Companies by Sales Force Effectiveness Shows Improvement in Q1]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10002138/ranking-of-20-drug-companies-by-sales-force-effectiveness-shows-improvement-in-q1/]]></link>
		<description><![CDATA[A ranking of 20 drug companies on sales and marketing productivity shows upward trends in effectiveness in Q1 2009. At the top of the table is AIDS drug specialist Gilead. At the bottom of the table is vanity pharma play Medicis. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 14 May 2009 09:06:10 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/sales+force.html"><![CDATA[Sales Force]]></category>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/marketing+research.html"><![CDATA[Marketing Research]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Wyeth v. Levine's Unintended Consequences: Prescription Data-Mining Banned in Vermont]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001826/wyeth-v-levines-unintended-consequences-prescription-data-mining-banned-in-vermont/]]></link>
		<description><![CDATA[A federal court in Vermont has upheld a law preventing drug companies from "data-mining" prescription information from pharmacies. The court cited the U.S. Supreme Court's Wyeth v. Levine anti-preemption ruling as one of its reasons in doing so, suggesting that the Wyeth decision will consequences far beyond personal injury class-actions....]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 27 Apr 2009 09:23:15 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/vermont.html"><![CDATA[Vermont]]></category>
		<category domain="http://resources.bnet.com/topic/levine.html"><![CDATA[Levine]]></category>
		<category domain="http://resources.bnet.com/topic/data+mining.html"><![CDATA[Data Mining]]></category>
		<category domain="http://resources.bnet.com/topic/business+intelligence.html"><![CDATA[Business Intelligence]]></category>
		<category domain="http://resources.bnet.com/topic/marketing+research.html"><![CDATA[Marketing Research]]></category>
		<category domain="http://resources.bnet.com/topic/databases.html"><![CDATA[Databases]]></category>
		<category domain="http://resources.bnet.com/topic/enterprise+software.html"><![CDATA[Enterprise Software]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[Software]]></category>
		<category domain="http://resources.bnet.com/topic/data+management.html"><![CDATA[Data Management]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">WYE</category>
	</item>
	<item>
		<title><![CDATA[14 Drug Companies Cited for Misleading Google Ads]]></title>
		<link><![CDATA[http://industry.bnet.com/advertising/10001524/14-drug-companies-cited-for-misleading-google-ads/]]></link>
		<description><![CDATA[The FDA cited 14 drug companies for misleading advertising in sponsored ads among Google search results.    Those cited: Biogen Idec, Sanofi Aventis, GlaxoSmithKline, Forest Laboratories, Cephalon, Bayer, Johnson & Johnson, Pfizer, Novartis , Genentech, Boehringer Ingelheim, Merck, Hoffman-LaRoche, and Eli Lilly.    The citations, sent...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 07 Apr 2009 12:44:01 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/google+inc..html"><![CDATA[Google Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/bayer+ag.html"><![CDATA[Bayer AG]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/advertisement.html"><![CDATA[Advertisement]]></category>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/sanofi-aventis.html"><![CDATA[Sanofi-Aventis]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BAYR Y</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GOOG</category>
		<category domain="tickers">BAYR Y,GOOG</category>
	</item>
	<item>
		<title><![CDATA[Tafas v. Doll: Drug Companies Face New Limits on Patents]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001424/tafas-v-doll-drug-companies-face-new-limits-on-patents/]]></link>
		<description><![CDATA[Drug companies will be dismayed by a federal appeals court ruling that came down on Friday which gives the U.S. Patent and Trademark Office new powers to limit the way patents are filed.    The drug business depends heavily on its ability to patent chemicals and processes for...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 23 Mar 2009 06:59:01 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/patent.html"><![CDATA[Patent]]></category>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/rule.html"><![CDATA[Rule]]></category>
		<category domain="http://resources.bnet.com/topic/drug+business.html"><![CDATA[Drug Business]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[NPR Producer: Goodwin Broke "Ironclad" Contract Over GSK Cash; Pitts Didn't Disclose Ties]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001303/npr-producer-goodwin-broke-ironclad-contract-over-gsk-cash-pitts-didnt-disclose-ties/]]></link>
		<description><![CDATA[The producer of an NPR radio show has accused the show's host, Fred Goodwin, of breaking his contract by failing to disclose his ties to drug companies.    The producer also denies that Peter Pitts, a former FDA official and an executive at Manning, Selvage & Lee, a...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 09 Mar 2009 06:40:11 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/npr.html"><![CDATA[NPR]]></category>
		<category domain="http://resources.bnet.com/topic/radio.html"><![CDATA[Radio]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/tie.html"><![CDATA[Tie]]></category>
		<category domain="http://resources.bnet.com/topic/satellite+radio.html"><![CDATA[Satellite Radio]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/advertising+%2526+promotion.html"><![CDATA[Advertising & Promotion]]></category>
		<category domain="http://resources.bnet.com/topic/public+relations.html"><![CDATA[Public Relations]]></category>
		<category domain="http://resources.bnet.com/topic/consumer+electronics.html"><![CDATA[Consumer Electronics]]></category>
		<category domain="http://resources.bnet.com/topic/personal+technology.html"><![CDATA[Personal Technology]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+communications.html"><![CDATA[Corporate Communications]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Ranking of 20 Drug Companies' Sales Forces Shows Productivity Flat or Declining]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001144/ranking-of-20-drug-companies-sales-forces-shows-productivity-flat-or-declining/]]></link>
		<description><![CDATA[A ranking of drug company sales productivity shows Gilead gets the most revenues in return for every dollar invested in reps and marketing.    At the other end of the table, Sepracor gets the least bang for its sales, general and administrative buck see table below.  ...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 24 Feb 2009 09:47:51 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force.html"><![CDATA[Sales Force]]></category>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/genentech+inc..html"><![CDATA[Genentech Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sepracor+inc..html"><![CDATA[Sepracor Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SEPR</category>
		<category domain="tickers">DNA,PFE,SEPR</category>
	</item>
	<item>
		<title><![CDATA[NEJM: Foreign Drug Trials Could Hurt U.S. Patients]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001071/nejm-foreign-drug-trials-could-hurt-us-patients/]]></link>
		<description><![CDATA[The increasing use of foreign drug trials may hurt U.S. patients because of genetic and environmental differences in overseas study subjects, a new study in the New England Journal of Medicine suggests. "Are trial results accurate and valid, and can they be extrapolated to other settings?" asks a team from...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 19 Feb 2009 07:56:45 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/u.s..html"><![CDATA[U.S.]]></category>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/india.html"><![CDATA[India]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/vaccine.html"><![CDATA[Vaccine]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[Clinical Trial]]></category>
		<category domain="http://resources.bnet.com/topic/trial.html"><![CDATA[Trial]]></category>
		<category domain="http://resources.bnet.com/topic/argentine+authority.html"><![CDATA[Argentine Authority]]></category>
		<category domain="http://resources.bnet.com/topic/gsk.html"><![CDATA[GSK]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Novartis, Boehringer Start Using Twitter Accounts]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001062/novartis-boehringer-start-using-twitter-accounts/]]></link>
		<description><![CDATA[AstraZeneca, Novartis, Vertex Pharmaceuticals and Boehringer Ingelheim have started experimenting with Twitter with varying degrees of enthusiasm, reports Pharmaceutical Executive.    Drug companies have so far looked at social media with a mixture of fear and loathing. They believe perhaps wrongly that giving consumers more opportunities to talk...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 18 Feb 2009 10:02:53 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/social+media.html"><![CDATA[Social Media]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/twitter.html"><![CDATA[Twitter]]></category>
		<category domain="http://resources.bnet.com/topic/az.html"><![CDATA[AZ]]></category>
		<category domain="http://resources.bnet.com/topic/bi+site.html"><![CDATA[BI Site]]></category>
		<category domain="http://resources.bnet.com/topic/pricing.html"><![CDATA[Pricing]]></category>
		<category domain="http://resources.bnet.com/topic/business+intelligence.html"><![CDATA[Business Intelligence]]></category>
		<category domain="http://resources.bnet.com/topic/tools+%2526+techniques.html"><![CDATA[Tools & Techniques]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/enterprise+software.html"><![CDATA[Enterprise Software]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[Software]]></category>
		<category domain="http://resources.bnet.com/topic/data+management.html"><![CDATA[Data Management]]></category>
		<category domain="http://resources.bnet.com/topic/management.html"><![CDATA[Management]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">NVS</category>
	</item>
	<item>
		<title><![CDATA[FDA to Allow "Off-Label" Unapproved Drug Promotion]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000591/fda-to-allow-off-label-unapproved-drug-promotion/]]></link>
		<description><![CDATA[The FDA has "finalized" guidelines allowing drug companies to promote drugs for unapproved ("off-label") uses. The guidelines will allow companies to distributeÂ  peer-reviewed scientific literature discussing off-label uses.    Drug companies and their right-wing stalking horse, the Washington Legal Foundation, have been pushing for this move for years....]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 13 Jan 2009 08:11:16 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Drug Makers Gave Lobbyists an Xmas Gift -- Millions More to Lobby Obama Administration]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000547/drug-makers-gave-lobbyists-an-xmas-gift-millions-more-to-lobby-obama-administration/]]></link>
		<description><![CDATA[A New Year will bring a new president, a new FDA chief, many new drug regulations, and, possibly, health insurance reform. Mindful of the ton of major drug brands that will go off-patent in 2009, drug companies have not rested in their lobbying efforts over generics and patent issues. They...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 31 Dec 2008 11:36:49 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/vaccine.html"><![CDATA[Vaccine]]></category>
		<category domain="http://resources.bnet.com/topic/administration.html"><![CDATA[Administration]]></category>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+congress.html"><![CDATA[U.S. Congress]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/health+care.html"><![CDATA[Health Care]]></category>
		<category domain="http://resources.bnet.com/topic/drug.html"><![CDATA[Drug]]></category>
		<category domain="http://resources.bnet.com/topic/teva.html"><![CDATA[Teva]]></category>
		<category domain="http://resources.bnet.com/topic/biotech+drug.html"><![CDATA[Biotech Drug]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/vertical+industries.html"><![CDATA[Vertical Industries]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/enterprise+software.html"><![CDATA[Enterprise Software]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[Software]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[FDA Caves to Pfizer, Industry on Antibiotics Ruling]]></title>
		<link><![CDATA[http://industry.bnet.com/food/1000325/fda-caves-to-pfizer-industry-on-antibiotics-ruling/]]></link>
		<description><![CDATA[The Food and Drug Administration has quietly withdrawn its order banning extralabel use of the antibiotic cephalosporin, so that it can "fully consider the comments" it has received on the issue.    When the agency announced the order on July 3, drug companies and agriculture groups were outraged....]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 12 Dec 2008 09:05:56 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/katherine+glover.html"><![CDATA[Katherine Glover]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
</channel>
</rss>
